Table 3.
The antibody drugs for GPCRs
| Drugs | Target | Phase | Indications | References |
|---|---|---|---|---|
| Erenumab | CGRP | Approved | Migraine,Temporomandibular joint dysfunction syndrome, Headache | [332] |
| Mogamulizumab | CCR4 | Approved | Cancer, Adult T-cell Leukemia/Lymphoma (ATLL), Cutaneous T-cell Lymphoma (CTCL) | [333–336] |
| Leronlimab | CCR5 | Phase III | COVID-19 Pneumonia, Metastatic microsatellite-stabilized colorectal cancer, Nonalcoholic steatohepatitis | [337] |
| Talquetamab | GPRC5D | Phase III | Multiple Myeloma, Plasma cell myeloma refractory, Recurrent Multiple Myeloma | [338, 339] |
| REMD-477 | GCGR | Phase II | Type 1 diabetes, Type 2 diabetes, Glucose intolerance | [340, 341] |
| Plozalizumab | CCR2 | Phase II | Diabetic nephropathy, Melanoma | [342] |
| LY-3,041,658 | CXCR1 and CXCR2 | Phase II | Hidradenitis suppurativa | [343, 344] |
| Avdoralimab | C5aR1 | Phase II | Advanced Solid Tumors, COVID-19 Pneumonia,Herpetic pemphigoid | [345] |
| Volagidemab | GCGR | Phase II | Type 1 diabetes, Type 2 diabetes, Glucose intolerance | [340, 341] |
| AMG-301 | PAC1R | Phase II | Migraine | [346] |
| Getagozumab | ETAR | Phase II | Pulmonary arterial hypertension | [347, 348] |
| Tidutamab | SSTR2 | Phase II | Merkel cell carcinoma, Small Cell Lung Cancer, Gastrointestinal Mesenchymal Tumor, Neuroendocrine Tumor | [349] |
| Nimacimab | CB1 | Phase II | Diabetic gastroparesis, Diabetic nephropathy, Nonalcoholic steatohepatitis, Obesity | [350] |
| Ulocuplumab | CXCR4 | Phase II | Pancreatic Cancer, Multiple Myeloma, Acute Myeloid Leukemia, Macroglobulinemia | [351, 352] |
| LM-305 | GPRC5D | Phase I/II | Multiple Myeloma, Solid Tumors, Hematologic Diseases | [353] |
| TAK-500 | CCR2 | Phase I | Breast Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Solid tumor, Head and Neck Squamous Cell Carcinoma, Gastric cancer | [354] |
| JBH492 | CCR7 | Phase I | B-cell chronic lymphocytic leukemia, Non-Hodgkin’s Lymphoma | [355, 356] |
| HZ-515H7 | CXCR4 | Phase I | Neoplasms | [357, 358] |
| SAR-113,244 | CXCR5 | Phase I | Systemic lupus erythematosus | [359] |